Innovation1 Biotech Inc. (IVBT)
| Market Cap | 4.49K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.21M |
| Shares Out | 22.47M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153 |
| Average Volume | 1,717 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0002 - 0.0050 |
| Beta | 17.11 |
| RSI | 39.87 |
| Earnings Date | Apr 17, 2026 |
About Innovation1 Biotech
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long covid and other viral indications. The company is based in New York, New York. [Read more]
Financial Performance
News
Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1'' or the “Company”), a small molecule drug discovery company focused on the clinical development of mo...
Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1'' or the “Company”), a small molecule drug discovery company focused on the clinical development of mod...
Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D.
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or the “Company”), a small molecule drug discovery company focused on the clinical development of modi...
Innovation1 Biotech (IVBT) Completes Name and Ticker Symbol Change from Gridiron BioNutrients (GMVP)
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or the “Company”), a small molecule drug discovery company focused on the clinical development of mod...